Related Experiment Video
Updated: Sep 23, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
Amitesh Verma1,2, Sarwish Rafiq3,4
1Winship Summer Scholars Research Program, Emory University, Atlanta, GA, USA.
Abstract:
Genetic modification of T cells to express chimeric antigen receptors (CARs) has yielded remarkable clinical outcomes and initiated a novel era for cancer immunotherapy. The impressive clinical responses seen in hematologic malignancies have led to the investigation of CAR T cells in solid tumors but attaining similar results has been challenging to date. Glioblastoma (GBM) presents a particularly challenging malignancy for treatment and despite some progress in treatments over the past decade, prognosis remains poor for the vast majority of patients. However, recent data support the clinical efficacy and safety of CAR T cell therapy in GBM. In this review, common challenges associated with treating GBM will be discussed in addition to how CAR T cells can overcome such barriers. Additionally, emerging techniques of optimizing CAR T cell therapy for GBM will be emphasized, highlighting the prospective promise of cellular immunotherapy.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for glioblastoma (GBM), a challenging brain cancer. This review discusses overcoming treatment barriers and optimizing CAR T cells for improved outcomes in GBM patients.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- CAR T cell therapy has revolutionized hematologic cancer treatment.
- Translating CAR T cell success to solid tumors, like glioblastoma (GBM), remains a significant challenge.
- Despite advances, GBM prognosis is poor, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the challenges in treating glioblastoma (GBM).
- To explore how CAR T cells can overcome GBM-specific treatment barriers.
- To highlight emerging strategies for optimizing CAR T cell therapy in GBM.
Main Methods:
- Review of current literature on CAR T cell therapy in glioblastoma.
- Analysis of challenges in GBM treatment and potential CAR T cell solutions.
- Discussion of novel approaches to enhance CAR T cell efficacy for GBM.
Main Results:
- CAR T cell therapy demonstrates clinical efficacy and safety in GBM patients.
- CAR T cells offer potential mechanisms to overcome GBM's complex tumor microenvironment.
- Emerging techniques show promise for improving CAR T cell performance in GBM.
Conclusions:
- CAR T cell therapy represents a promising frontier for glioblastoma treatment.
- Overcoming GBM-specific challenges is key to realizing the full potential of CAR T cells.
- Optimized CAR T cell strategies offer hope for improved glioblastoma patient outcomes.
